Press "Enter" to skip to content

Adding Apalutamide to ADT Prolongs Survival in mCSPC – Cancer Therapy Advisor

admin 0

Adding Apalutamide to ADT Prolongs Survival in mCSPC  Cancer Therapy Advisor

In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% …

“prostate cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *